Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9*1/*3 and VKORC1-1639G/A genotype.
J Clin Pharm Ther
; 44(6): 977-980, 2019 Dec.
Article
em En
| MEDLINE
| ID: mdl-31468576
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Lenvatinib inhibits CYP2C8. (S)-Warfarin is metabolized to (S)-7-hydroxywarfarin by CYP2C9 and (S)-4'-hydroxywarfarin by CYP2C8. Here, we report drug interactions between warfarin and lenvatinib in a patient with CYP2C9*1/*3. CASESUMMARY:
The patient was administered warfarin. His international normalized ratio (INR) was 1.92 before lenvatinib administration. On day 8 after beginning 12 mg/day lenvatinib, plasma trough concentrations of lenvatinib and (S)-warfarin were 33.3 ng/mL and 0.67 µg/mL, respectively. On day 10, his INR increased to 3.48. WHAT IS NEW ANDCONCLUSION:
Lenvatinib-dependent (S)-warfarin inhibition could involve CYP2C9 and CYP2C8. After initiating warfarin plus lenvatinib, INR assays are necessary.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Compostos de Fenilureia
/
Quinolinas
/
Varfarina
/
Interações Medicamentosas
/
Vitamina K Epóxido Redutases
/
Citocromo P-450 CYP2C9
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article